Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses DREAMM-2 (NCT03525678), an open-label, two-arm, Phase II study investigating belantamab mafodotin for relapsed or refractory (R/R) multiple myeloma. Belantamab mafodotin is an immunoconjugate targeting B-cell maturation antigen and has shown single-agent activity in the Phase 1 DREAMM-1 study in heavily pre-treated patients with R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.